Introduction
In 2010, there was an estimated 68 130 new cases of melanoma and 8700 deaths in the USA [1] . Patients with stage IIB to IIIC melanoma have a lifetime risk of melanoma-related mortality of 30-60% [2] . Most recurrences are detected within the first 2 to 3 years after diagnosis of the primary and/or regional nodal disease [3] . No general consensus exists regarding the optimal followup strategy for patients at a high risk of disease recurrence. However, it is generally accepted that the goal of surveillance approaches is to detect recurrent disease at a time when it is most treatable. Patients with high-risk melanoma often undergo extensive staging studies including computed tomography (CT), PET, and/or MRI before surgical management and as part of routine follow-up. However, routine imaging has not been shown to be clinically useful in this setting [4] [5] [6] . Several retrospective studies evaluating the methods of detection of first disease recurrence have demonstrated that most recurrences are detected by the patient as either a new symptom or by the patient or physician as a new physical finding [3, [7] [8] [9] . Furthermore, there appeared to be no difference in survival based on whether the recurrence was detected by the patient or the physician [3, 7, 10] . This was affirmed recently in a large retrospective study involving follow-up patients with stage III disease. This study showed that 47% of first recurrences were discovered by the patient or family member and further suggested that physical examination beyond 3 years for patients with stage IIIA, 2 years for patients with stage IIIB and 1 year for patients with stage IIIC would detect few recurrences, as less than or 5% of patients had local/regional recurrences after these time points [11] .
Currently, the National Comprehensive Cancer Network guidelines suggest that patients with high-risk melanoma should undergo a history and physical examination every 3-6 months for 2 years, then every 3-12 months for 3 years and then annually as clinically indicated [12] . In addition, chest radiograph, CT and/or PET-CT scans as well as annual brain MRI is suggested to be considered in screening for recurrence. Routine laboratory testing and imaging are not recommended after 5 years [12] . Thus, despite the lack of supportive data, many patients with a history of melanoma who are asymptomatic continue to undergo serial routine surveillance imaging aimed at the detection of distant disease relapse.
The surveillance approach for patients with stage IIB-IIIC melanoma managed by Beth Israel Deaconess Medical Center (BIDMC) Cutaneous Oncology Program (COP) involves visits every 6 weeks for the first 6 months postsurgery, then every 3 months until 3 years, then every 6 months until 5 years, and annually, thereafter. Patients are subjected to a focused history, physical examination and have a complete blood count and serum lactate dehydrogenase measured at each visit. Surveillance chest radiographs are performed every other visit for the first 5 years and annually after 5 years. CT scans or other imaging are not routinely performed and are only obtained in the setting of worrisome new symptoms, physical findings, or laboratory or chest radiograph abnormalities. In 2004, the COP began performing restaging CT scans of the torso and head imaging 3 years from completion of local-regional therapy or initiation of adjuvant treatment in patients with stage IIB-IIIC melanoma. The goal was to provide an additional measure of confidence of diseasefree status before moving from 3-to-6-month interval follow-up visits. Five and a half years into this practice, we examined the COP patient database to determine the utility and cost effectiveness of this approach.
Methods
This study involved a retrospective review of patients diagnosed with stage IIB-IIIC melanoma between January 2001 and July 2006 and followed within the COP at BIDMC. Patients who underwent routine restaging head CT/MRI and torso CT scans 3 years after completion of their local-regional therapy or initiation of their adjuvant treatment were identified from the existing COP database of over 2000 patients with melanoma. Formal analysis was restricted to those patients who were over 18 years of age, free from disease recurrence, and remained asymptomatic at the time of their 3-year follow-up imaging. Imaging occurred between January 2004 and July 2009. Baseline demographic and disease characteristics of all patients diagnosed with stage IIB-IIIC melanoma in this time period were documented. Information was collected regarding their disease outcome, treatment, and followup imaging. The standard follow-up schedule involved visits every 6 weeks for the first 6 months postsurgery, then every 3 months until 3 years, then every 6 months until 5 years, and annually, thereafter. Thus, most patients were seen at 3-month intervals during the 3-year time period and had chest radiographs every 6 months. With rare exceptions, torso CT or head CT/MRIs were performed only for patients with new symptoms, physical findings, and laboratory or chest radiograph abnormalities. This research study was approved by the Dana Farber/ Harvard Cancer Center Institutional Review Board.
Findings on the 3-year imaging studies were categorized as either (i) true positive, (ii) false positive, or (iii) normal. Follow-up procedures arising from the positive findings were documented and the cost per true-positive diagnosis of recurrent melanoma was determined using the standard cost for each imaging procedure during the follow-up imaging time period. The cost for head MRI was $5195, for head CT $2734 and torso CT $7592. Additional costs of follow-up imaging or biopsy procedures for patients with abnormal 3-year imaging were also estimated and added to the overall cost of surveillance. The medical records were reviewed to a median follow-up of 23 months after 3-year imaging and patient outcomes were documented.
Statistical considerations
Outcomes were determined by review of the raw data contained in the COP Database. Fisher's exact tests and Wilcoxon two-sample tests were used to compare clinial features such as age, sex, location of tumor, Breslow thickness of tumor, Clark level, disease stage, and interferon (IFN) useage (yes or no) between the group of patients who underwent 3-year scans and those who did not undergo 3-years scan. A Kaplan-Meier curve was used to plot relapse-free survival. Relapse-free survival was defined as the time from melanoma diagnosis to recurrence or death. All tests were two sided with a level at 0.05. The result was determined to be statistically significant if the P value of the test was less than 0.05.
Results
Four hundred thirty-nine patients were identified with stage IIB-IIIC melanoma during the designated time frame. Of these, 52 patients (12%) underwent 3-year follow-up CT scan/MRI and met study criteria. An additional 158 (36%) patients who did not undergo 3-year imaging continued to be followed at BIDMC. The remaining patients were followed in their local communities or otherwise lost to follow-up. Characteristics of the 210 patients who were at BIDMC are displayed in Table 1 separated by whether they did or did not undergo 3-year follow-up imaging. The 52 patients with 3-year follow-up imaging contained a slightly lower proportion of patients with stage IIIB disease (19 vs. 27%, P = 0.28), a significantly higher proportion of patients with stage IIIA disease (35 vs. 9%, P < 0.0001), and significantly higher percentage of patients who received adjuvant IFN (87 vs. 63%, P = 0.0017), than the 158 patients who did not undergo 3-year follow-up imaging. Otherwise the two groups were very similar. Median age for the population as a whole was 54 years, 59% were males and 23% had been diagnosed with stage II disease.
The imaging studies and disease outcomes of the 210 patients followed within the BIDMC COP are displayed in Table 2 . Of these 210 patients, 115 (55%) experienced disease recurrence (101 recurred before 3 years and 14 at or after 3 years). Of the 101 patients whose disease recurred before 3 years, 70 (69%) recurrences were identified by symptoms, nine (8%) by physical examination, three by laboratory testing, and five by routine chest radiograph. The majority of the patients recurring with symptoms noted skin or subcutaneous nodules or lymphadenopathy (75%). The reminder had neurological symptoms (9%), pain (6%), pathological fracture, hemoptysis, ascites, lymphedema, systemic symptoms, or pharyngitis from a metastatic deposit. Recurrences from 15 patients (15%) were first identified on more sophisticated imaging (13 CT scans, one liver ultrasound, and one PET-CT). Given that routine imaging other than chest radiograph was not a standard procedure in the COP, the reason for imaging was documented. Eight patients were on clinical trials that required CT scans, two had CT scans by physicians outside of BIDMC for restaging, one had liver ultrasound follow-up another medical issue that incidentally identified recurrence, and three underwent scans at BIDMC for restaging for unspecified reasons. Of the patients recurring before 3 years, 70 (69%) have died of melanoma, one died of colon cancer, and one died of unknown causes. The median time to recurrence was 12 months (Fig. 1) , and the median time from recurrence to death was 13 months.
Fifty-seven patients who remained asymptomatic and recurrence free at the 3-year time point did not undergo Stage  IIB  6  12  27  17  33 16  IIC  4  8  11  6  14  7  IIIA  18  35  15  10  33 16  IIIB  10  19  43  27  53 25  IIIC  14  27  62  39  76 36  Interferon  Yes  45  87  100  63  145 69  No  7  13  58  37  65 31 BIDMC, Beth Israel Deaconess Medical Cente; NA, not applicable. the proposed restaging imaging. This largely reflected incomplete initial uptake of the new staging policy as 49% of these patients crossed their 3-year follow-up threshold by January 2006 (2 years after the policy was first proposed). In this group of patients, nine eventually developed recurrence following the 3-year time point, with seven (78%) being detected based on symptoms, with the remaining two (22%) being identified based on examination or chest radiograph. Of these nine patients, three (33%) have died of melanoma, whereas the remaining six patients are alive at a median follow-up of 23 months from diagnosis of stage IV. The median months to recurrence in this group of nine patients was 53 months, and the median number of months from recurrence to death for the three patients who have died was 34 months.
Of the 52 patients undergoing imaging at the 3-year time point, there was one false positive and no true positive head CT/MRIs and three false positive and two truepositive torso CTs (Table 3 ). The total cost including 3year follow-up scans, additional imaging (one repeat head CT, two additional chest CTs, one repeat CT torso, one abdominal MRI) and diagnostic procedures (one CTguided lung biopsy and one pelvic lymph node biopsy) was $625 980 (Table 4 ). Thus, the cost per diagnosis of melanoma recurrence was $312 990.
Both the patients with true-positive scans developed symptomatic recurrence within 1 week of positive imaging and died at 1 and 6.5 months after the diagnosis of distant metastatic disease ( Table 5 ). In the remaining 50 patients, at a median follow-up of 23 months after the 3-year follow-up imaging, two patients have developed symptomatic distant metastatic melanoma with one patient succumbing to this disease and one patient has developed a local/regional recurrence that was detected on physical examination and was surgically resected.
Discussion
Currently, there are no standardized guidelines regarding routine surveillance imaging in patients with high-risk melanoma. Three single-institution studies evaluated the role of CT imaging at the time of diagnosis in patients with documented local-regional metastases and with a normal chest radiograph and lactate dehydrogenase [8, 9, 13] . These series demonstrated a low true-positive rate (4-16%) and a higher false-positive rate (8-22%) [8, 9, 13] . Despite the low yield in detecting distant metastases in patients with stage III disease, the percentage of true-positive findings is not insignificant, making further imaging reasonable in this patient population, especially in patients with inguinal nodal disease who are being considered for inguinal and possibly pelvic node dissection. The utility of subsequent imaging in such patients has not been fully examined.
Relapse-free survival data in patients with stage IIB-IIIC melanoma suggest that 30-80% of patients will experience a tumor recurrence with 50-80% of those recurrences happening within 3 years of initial presentation [3, 14] . Consequently, many programs recommend more intensive patient follow-ups in the first 3 years after surgical management in patients with high-risk melanoma with subsequent follow-up being reduced to every 6 months. Given that most disease recurrences are detected through careful history and physical examination and that these would be less frequent following the 3-year milestone, we sought to determine whether restaging head and torso imagings at the 3-year follow-up time point, before lengthening the routine follow-up interval, could identify sufficient numbers of patients with then asymptomatic disease for whom such extended interval follow-up would be inappropriate. Having incorporated routine restaging head CT or head MRI and torso CT scans for patients remaining asymptomatic 3 years after initial diagnosis, we sought to determine not only the yield of this approach, but also its cost effectiveness.
Of the 439 patient charts reviewed, 229 patients (52%) were followed elsewhere and 210 (48%) were followed at BIDMC. Of those followed at BIDMC 115 patients (55%) developed disease recurrence with a median follow-up of close to 5 years. Although these figures are consistent with the published recurrence risks for the stage IIB-IIIC patient population, it is likely that higher risk patients chose to maintain their follow-up at BIDMC and furthermore, other patients returned to BIDMC when they developed symptoms or physical findings possibly reflecting recurrence. Therefore, this recurrence percentage most likely overstates the recurrence risk for the 439 patients as a whole.
Of note, 101 (88%) of these recurrences happened before the 3-year time point (median 12 months, 95% confidence interval: 10-16 months). This median relapsefree survival and percentage relapse at 3 years are also consistent with the published literature for this high-risk patient population. In two randomized controlled trials Eastern Cooperative Oncology Group E1684 and Intergroup E1690 comparing high-dose IFN-a 2b versus observation in patients with resected stage IIB-III melanoma demonstrated a statistically significant improvement in relapsefree survival but little to no benefit in overall survival [14, 15] . Given that 87% of patients in this study received adjuvant IFN treatment, which has been reported to prolong median relapse-free survival by around 8-9 months [14] , this median time to recurrence of 12 months in our cohort is surprisingly short. This further suggests a potential bias toward those patients experiencing recurrence being more likely to be followed at BIDMC.
Nonetheless, these data also suggest that our general screening approach of omitting CT imaging did not result in a significant delay in diagnosis of melanoma recurrence relative to the published literature.
Retrospective studies have shown that 80-90% of recurrences are discovered by history and physical examination, rather than by imaging or laboratory tests [16] [17] [18] [19] . A prospective study was performed at the Sydney Melanoma Unit of patients with stage I, II, or III melanoma to determine the value of surveillance studies [10] . Of all recurrences, 73% were detected by the patient. There was no statistically significant difference in survival between patients who discovered the recurrence themselves versus those discovered by physicians [10] . These findings were consistent with our findings that 69% (79/ 115) of patients who recurred presented with symptoms. However, given our more regimented follow-up schedule the majority of recurrences in our population were detected by the physician either by history or physical examination.
Three-year follow-up imaging performed in the 52 patients in this study revealed six abnormal scans; of which four were false positive. Given that 85% of recurrences happen before the 3-year time point and 80% of those recurrences are detected by history or physical examination, it is not surprising that routine imaging at the 3-year time point did not detect many recurrences. Furthermore, the fact that the two patients documented to have true disease recurrence at the 3-year time point developed symptomatic disease within 1 week of their imaging, further undercuts the value of such delayed 'landmark' imaging as a clinical tool. The cost of 3-year follow-up imaging and related diagnostic testing for the 52 patients in this analysis was estimated to be $625 980. Thus, the cost per diagnosis of metastatic disease was $312 990. Although undoubtedly the imaging provided some comfort to those patients who received clean reports, this unquantifiable benefit must be balanced against the likely emotional distress and physical and perhaps economic consequences associated with additional testing that was experienced by the four patients (8%) with false-positive scans. Thus, in this time of increasing cost consciousness, it is hard to justify the performance of such routine landmark-based imaging.
Furthermore, given the low risk of recurrence beyond 3 years, it is likely that subsequent routine imaging would have similarly low utility. A recent study of stage III melanoma patients suggests that routine imaging after 2 years in stage IIIC patients and after 3 years in stages IIIA and IIIB would likely detect only a small number of recurrences [11] . This is the current follow-up schedule used by the BIDMC COP. Whether such routine imaging may have value within the first 12-18 months, when the majority of recurrences are likely to occur, remains to be assessed. However, given that the vast majority of recurrences are picked up by symptoms and physical examination and the lack of current evidence that earlier detection is associated with improved outcome, documentation of such a role for earlier imaging seems unlikely. The BIDMC COP follow-up schedule, omitting the 3-year imaging, is sufficient in identifying the majority of recurrences and therefore represents a practical and effective follow-up strategy.
